Get Exclusive App Deals
English
  1. Home
  2. Japan
  3. Kyushu
  4. Oita
  5. Takeda

Takeda

Travel Info

Top activities in Takeda

Latest update

Walking around

More destinations

Takeda Weather and climate

Data source：Meteostat
Update date：2025-09

Takeda year round climate
  • Spring (March–May): Average 50–66°F, mild climate but with more rainfall, especially in April and May. Common activities: Spring outings, flower viewing. Recommended clothing: Light jacket, long-sleeved shirt, and rain gear.
  • Summer (June–August): Average 74–85°F, hot and humid with abundant rainfall. Common activities: Summer resorts, water activities (if facilities are available). Recommended clothing: Light and breathable clothing, short sleeves, and shorts, and rain gear.
  • Autumn (September–November): Average 66–80°F, comfortable and pleasant climate with gradually decreasing rainfall. Common activities: Maple viewing (if maple leaves are present), outdoor excursions. Recommended clothing: Long-sleeved shirt, light jacket.
  • Winter (December–February): Average 41–44°F, cold and dry with the least rainfall. Common activities: Hot spring trips (if facilities are available), indoor activities. Recommended clothing: Warm coat, sweater, scarf, gloves.
Takeda climatological average

Annual average temperature: approx. 63.0°F / Annual rainfall: approx. 1598 mm / Summer humidity: 70%–80% / Rainiest month: August

Takeda monthly average temperature and precipitation
Month
Air temperature (°F)
Precipitation (mm)
January
41.2°F
47.4
February
43°F
53.8
March
50.9°F
115.7
April
61.5°F
158.9
May
66.7°F
199.8
June
74.7°F
248.8
July
84°F
176
August
85.1°F
254.7
September
80.8°F
127.3
October
66.4°F
105.2
November
57°F
91.9
December
45°F
19.2
Takeda weather for the next seven days
10/17
Friday
Patchy rain nearby
79.1°F/65.8°F
10/18
Saturday
Patchy rain nearby
80.6°F/63.9°F
10/19
Sunday
Patchy rain nearby
69.7°F/62°F
10/20
Monday
Patchy rain nearby
74.7°F/59.9°F
10/21
Tuesday
Partly Cloudy
68°F/59.4°F
10/22
Wednesday
Overcast
65.6°F/57.7°F
10/23
Thursday
Sunny
69.4°F/53.8°F

Takeda FAQ

What is Takeda pharmaceutical company known for?
Takeda is known as a global pharmaceutical company that develops life-transforming medicines and therapies in its focus areas of oncology, rare diseases, gastroenterology, neuroscience, plasma-derived therapies, and vaccines. With a history dating back over 200 years, Takeda is recognized for its strong focus on research and development, strategic acquisitions like the takeover of Shire Plc, and its efforts to improve access to medicine and health care in emerging markets. Takeda is a research-driven biopharmaceutical company, heavily investing in R&D to discover and deliver innovative treatments. The company's R&D efforts focus on specific areas to cultivate expertise and accelerate the development of life-transforming medicines for patients.
What are Takeda's key therapeutic areas?
Takeda's key therapeutic areas of focus include oncology, rare diseases, gastroenterology, neuroscience, plasma-derived therapies, and vaccines.
Is Takeda a large pharmaceutical company?
Yes, Takeda is considered a 'big pharma' company. It is Japan's largest drugmaker and one of the top pharmaceutical companies in the world by revenue, a ranking that rose significantly following its merger with Shire. Takeda is a leading global biopharmaceutical company with a significant presence worldwide. The company's substantial acquisition of Shire was a major move that increased its size and global impact. Takeda invests heavily in research and development and is known for developing life-transforming treatments.
What is Takeda's top-selling drug?
Entyvio is frequently cited as Takeda's top-selling drug. It is a biologic therapy primarily used for the treatment of inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn's disease.
Why did Takeda restructure its programs?
Amid a broader profit decline catalyzed by patent losses, Takeda restructured. In the process, the company cut a series of programs for solid tumors and blood cancers and pivoted to autoimmune conditions, as many other cell therapy developers have amid a tough funding climate.